Immunovant (IMVT) Long-Term Debt Issuances (2019 - 2020)

Immunovant (IMVT) reported Long-Term Debt Issuances of $27.1 million for Q1 2020, up 200.0% quarter-over-quarter from -$27.1 million in Q4 2019.

Immunovant (IMVT) Long-Term Debt Issuances (2019 - 2020) Analysis & Trends

Immunovant has reported Long-Term Debt Issuances for 2 years, with the latest figure at $27.1 million in Q1 2020.

For the quarter ending Q1 2020, Long-Term Debt Issuances changed N/A year-over-year to $27.1 million; the trailing twelve-month figure through Dec 2020 stood at $27.1 million (changed N/A YoY), and the FY2020 full-year result was $35.0 million, changed N/A from the prior year.
Long-Term Debt Issuances for Q1 2020 stood at $27.1 million, up from -$27.1 million in the prior quarter.
The five-year high for Long-Term Debt Issuances was $27.1 million in Q1 2020, with the low at -$27.1 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	2.73 Mn
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Immunovant	5.71 Bn	5.71 Bn	-	-

Download Data